National Cancer Center

Ohara Pharmaceutical Co., Ltd.

H.u. Group Research Institute G.k.

Sysmex Corporation

Mukai, Hirofumi

Ushijima, Toshikazu

Toshikazu Ushijima

Satoshi Yamashita

Naoko Hattori

Hirofumi Mukai

Sako Magoichi

Masahro Maeda

The present invention provides a factor capable of predicting an effect of a medicinal therapy on a cancer such as HER2 positive cancer. More specifically, the present invention provides a method of predicting the effect of the medicinal therapy on the cancer, comprising:

Method of predicting effect of medicinal therapy on cancer

[Problem] To provide, in place of injected agents (such as Vidaza&#xae; and Dacogen&#xae;) clinically used as therapeutic drugs for high-risk myelodysplastic syndromes, a medicine as a therapeutic drug or a prophylactic drug for various advanced solid tumors, said medicine having high stability with respect to cytidine deaminase which is a hydrolytic metabolic enzyme, being absorbed into the body even by oral administration, and having an effect of being integrated into a nucleic acid biosynthetic route and inhibiting DNA methyltransferases, i.e., DNMTs. [Solution] The aforementioned problem is solved by a novel compound represented by formula (I). (In the formula, R is a hydroxyl group or a hydrogen atom, and Rand Rare each a benzyl group that may have a substituent.) 

DNMT inhibitor as solid tumor therapeutic drug

Growing community of inventors

Tokyo, Japan

Toshikazu Ushijima